About

Mark Snyder serves as Senior Vice President, Chief Legal Officer of Halozyme Therapeutics, and signs the Company's filings as Senior Vice President, General Counsel and Corporate Secretary. He commenced employment with Halozyme on January 3, 2022.

In 2025, Mr. Snyder played a key role in the negotiation and execution of two merger agreements through which Halozyme acquired two drug delivery technology companies, and oversaw the expansion of Halozyme's patent portfolio with multiple new patent filings related to Halozyme technologies. Under his leadership, the Company pursued infringement of its patents by Merck and was awarded a preliminary injunction in Germany, preventing Merck from launching Keytruda SC in Germany.

Roles

Halozyme Therapeutics, Inc.
Senior Vice President, Chief Legal Officer · Current role
2022–present
Qualcomm
Senior Vice President and Deputy General Counsel, Litigation
—
Kyocera Wireless
Manager, Intellectual Property Group
—
Sheridan Ross & McIntosh
Patent Attorney
—

Fixed Compensation

FY 2025
Salary
$619,000
ComponentAnnual base salary
All other compensation
$17,822
Total compensation
$4,531,568

Performance Compensation

Data from FY 2025

Cash incentive

Annual cash incentive
$394,613
FormNon-Equity Incentive Plan Compensation

Stock awards

Stock awards
$2,975,129
FormRSUs and PSUs
Option awards
$525,004
FormStock options

Also at Halozyme Therapeutics, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.